Ras gene causes cancer via different pathways in humans vs. mice

August 14, 2002

DURHAM, N.C. - Researchers at the Duke Comprehensive Cancer Center have found that a known cancer-causing gene, Ras, may exert its influence through very different pathways in humans than in mice, a finding that could offer tantalizing new targets for anti-cancer therapy.

While studying the Ras gene, Duke researchers unexpectedly found that it activates an obscure group of proteins in humans, but not in mice, in order to turn normal cells malignant. Yet many cancer treatments are based on data scientists derive from mouse models.

"Our study highlights a little-known pathway that appears to play a critical role in the ability of Ras to transform human cells, but not mouse cells, to become tumorigenic," said Christopher Counter, Ph.D., a cancer biologist at the Duke Comprehensive Cancer Center. "This pathway could present a new protein target for anti-cancer drugs in humans, and it reinforces the inherent differences between human and mouse cancers in terms of how they evolve."

Results of the Duke study are being published in the Aug. 15, 2002, issue of Genes and Development.

The Duke researchers decided to study oncogenic Ras, one of the first genes found to be involved in human cancers, because it is associated with very different malignancies in humans than in mice. Ras is activated in one-third of all human cancers, and as high as 90 percent in specific cancers, like pancreatic. In mice, Ras is associated with breast, skin and lung cancers.

Despite these differences, it was assumed that Ras signals the same set of proteins in mice as it does in humans for cells to become cancerous. The Duke scientists challenged this assumption and studied, for the first time, how Ras transforms human cells.

Team members Nesrin Hamad, Ph.D., and Joel Elconin, M.D., set out to map how Ras communicates with various signaling pathways that, when over-activated, ultimately command cells to proliferate uncontrollably. The scientists placed human and mouse cells in laboratory dishes, genetically modified the cells to express mutated forms of Ras, then traced how the protein produced by the Ras gene promoted cells to transform.

As expected, Ras exerted its malignant effects in mice cells primarily through a protein called Raf, whose specific job is to modify a chain of additional proteins that direct the cell's behavior to proliferate. Unexpectedly, Raf was not sufficient to turn normal human cells cancerous, the study found. Instead, in human cells the Ras gene appeared to activate a different protein pathway, called RalGEFs, to transform normal cells into cancer.

Little is known about RalGEFs, possibly because they have never been considered critical to human cancers, but researchers suspect that they may assist cells in ferrying molecules within and outside of cells -- a process called vesicle transport. How these functions relate to Ras' ability to transform normal cells into cancers remains unknown, said Counter. Nevertheless, the Duke study clearly showed that RalGEFs were necessary for the ability of Ras to transform normal human cells, he added.

"We propose that there are multiple proteins that Ras signals through in order to transform human cells, but there are significant differences in the relative potency of each pathway between humans and mice" Counter said. "The Ras oncogene appears to exert its function in humans through a pathway that was largely ignored."
-end-


Duke University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.